NASDAQ:CNSTConstellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNST stock has increased by 14.8% and is now trading at $37.39. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Constellation Pharmaceuticals.

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Constellation Pharmaceuticals.

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.62) by $0.01. View Constellation Pharmaceuticals' earnings history.

8 analysts have issued 12 month price objectives for Constellation Pharmaceuticals' shares. Their forecasts range from $35.00 to $75.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $50.29 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price. View analysts' price targets for Constellation Pharmaceuticals.

News articles about CNST stock have trended neutral recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Constellation Pharmaceuticals earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news aboutConstellation Pharmaceuticals.

Constellation Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,770,000 shares, a decrease of 11.9% from the April 30th total of 2,010,000 shares. Based on an average daily trading volume, of 373,400 shares, the days-to-cover ratio is currently 4.7 days. Currently, 7.7% of the shares of the company are short sold. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Evotec (EVTCY), Mirati Therapeutics (MRTX), PPD (SDGR), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN) and Blueprint Medicines (BPMC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Canopy Growth (CGC), Axsome Therapeutics (AXSM), AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Crispr Therapeutics (CRSP), Enphase Energy (ENPH), Novavax (NVAX), NVIDIA (NVDA) and Provention Bio (PRVB).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets acted as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include VR Adviser LLC (9.60%), Wellington Management Group LLP (5.60%), Cormorant Asset Management LP (4.88%), TRV GP LLC (3.67%), Regents of The University of California (3.58%) and BlackRock Inc. (3.14%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents and Patrick Trojer. View institutional ownership trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including TRV GP LLC, Cormorant Asset Management LP, Regents of The University of California, Casdin Capital LLC, Canada Pension Plan Investment Board, Two Sigma Investments LP, Morgan Stanley, and Soleus Capital Management L.P.. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Karen Valentine, Mark A Goldsmith, Of The University Of C Regents, and Patrick Trojer. View insider buying and selling activity for Constellation Pharmaceuticals.

CNST stock was purchased by a variety of institutional investors in the last quarter, including VR Adviser LLC, Victory Capital Management Inc., Victory Capital Management Inc., Wellington Management Group LLP, BlackRock Inc., Vivo Capital LLC, Franklin Resources Inc., and Trustees of Princeton University. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column, and James E Flynn. View insider buying and selling activity for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $37.39.

Constellation Pharmaceuticals has a market capitalization of $1.56 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.

The official website for Constellation Pharmaceuticals is www.constellationpharma.com.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]